PO.CL08.01 · 临床研究

8-O-乙酰哈帕苷诱导G2/M阻滞及其对下咽癌放射增敏作用的研究

Investigation of 8-O-acetylharpagide induced G2/M arrest and radiosensitization effects on hypopharyngeal cancer

海报缩略图:8-O-乙酰哈帕苷诱导G2/M阻滞及其对下咽癌放射增敏作用的研究
编号 6618 展板 19 时间 4/21 02:00–05:00 区域 Section 46 主讲 Wan-Yu Yang, MS
分会场 Radiation and Photodynamic Therapy Response Modifiers
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Wan-Yu Yang, Yi-Jang Lee

National Yang Ming Chiao Tung University, Taipei, Taiwan

摘要 Abstract

中文摘要
[目的] AT-1(8-O-乙酰哈帕苷,8-O-acetylharpagide)是从台湾特有植物筋骨草(Ajuga taiwanensis)中纯化的天然化合物,据报道具有抗衰老、抗炎和抗癌特性(如皮肤癌、肝癌和乳腺癌),但其在下咽鳞状细胞癌(HPSCC)中的潜在作用尚不清楚。本研究旨在系统性地表征人下咽癌细胞(FaDu)与正常人牙周韧带成纤维细胞(PDL)对AT-1的细胞反应,并评估其选择性细胞毒性和放射增敏潜力。 [方法] 采用MTT实验评估细胞活力。进行流式细胞术分析细胞周期分布和凋亡。通过免疫荧光染色和彗星实验评估DNA损伤。采用蛋白质印迹检测细胞周期和凋亡相关蛋白的变化。在AT-1预处理及随后X射线照射后检测放射敏感性。 [结果] AT-1选择性地降低FaDu细胞的活力,同时对PDL细胞的细胞毒性极小,并在FaDu中诱导明显的G2/M期阻滞,伴随Cyclin B1的异常上调和细胞周期调控因子的改变。凋亡分析显示,AT-1通过下调促存活蛋白(包括AKT、p-AKT和Bcl-2)触发细胞死亡。细胞内活性氧水平未显著增加,提示氧化应激并非AT-1诱导细胞毒性的直接原因。免疫荧光和彗星实验证实了AT-1处理的FaDu细胞中存在DNA双链断裂,这可能是所观察到的G2/M阻滞和凋亡的基础。此外,AT-1预处理增强了FaDu细胞的放射敏感性,而PDL细胞对单独的AT-1和联合治疗仍相对抵抗。AT-1通过扰乱细胞周期、诱导DNA损伤和促进凋亡来抑制下咽癌细胞的生长,并在该模型中作为选择性放射增敏剂。 [结论] 这些数据表明,AT-1(8-O-乙酰哈帕苷)诱导G2/M阻滞并选择性地使下咽癌细胞放射增敏,同时保护正常细胞。AT-1可能是一种有前景的低毒性放射增敏剂候选药物,可用于头颈癌,值得进一步开展体内和机制研究以明确其对DNA损伤应答的影响。
查看英文原文 English abstract
[Purpose] AT-1 (8-O-acetylharpagide) is a natural compound purified from the endemic Taiwanese plant Ajuga taiwanensis and has been reported to possess anti-aging, anti-inflammatory, and anti-cancer properties, such as skin, liver and breast, but its potential role in Hypopharyngeal squamous cell carcinoma (HPSCC) remains unclear. This study aimed to systematically characterize the cellular responses to AT-1 in human hypopharyngeal carcinoma cells (FaDu) versus normal human periodontal ligament fibroblasts (PDL) and to evaluate its selective cytotoxic and radiosensitizing potential. [Methods] Cell viability was assessed using the MTT assay. Flow cytometry was performed to analyze cell-cycle distribution and apoptosis. DNA damage was evaluated by immunofluorescence staining and comet assay. Western blotting was used to detect changes in cell cycle- and apoptosis-related proteins. Radiation sensitivity was examined following AT-1 pretreatment and subsequent X-ray exposure. [Results] AT-1 selectively reduced the viability of FaDu cells while exerting minimal cytotoxicity in PDL cells and induced pronounced G2/M phase arrest in FaDu, accompanied by abnormal upregulation of Cyclin B1 and modulation of cell cycle regulators. Apoptosis analysis revealed that AT-1 triggered cell death through downregulation of pro-survival proteins including AKT, p-AKT, and Bcl-2. Intracellular reactive oxygen species levels did not significantly increase, suggesting that oxidative stress was not directly responsible for AT-1-induced cytotoxicity. Immunofluorescence and comet assays confirmed the presence of DNA double-strand breaks in AT-1-treated FaDu cells, which may underlie the observed G2/M arrest and apoptosis. Furthermore, AT-1 pretreatment enhanced the radiosensitivity of FaDu cells, whereas PDL cells remained relatively resistant to AT-1 alone and to the combination treatment. AT-1 inhibits the growth of hypopharyngeal carcinoma cells by perturbing the cell cycle, inducing DNA damage, and promoting apoptosis, and it acts as a selective radiosensitizer in this model. [Conclusions] These data demonstrate that AT-1 (8-O-acetylharpagide) induces G2/M arrest and selectively radiosensitizes hypopharyngeal cancer cells while sparing normal cells. AT-1 may represent a promising low-toxicity radiosensitizer candidate for head and neck cancer, and further in vivo and mechanistic studies are warranted to define its impact on DNA damage response.
利益披露 Disclosure
W. Yang, None.

← 返回 AACR 2026 检索